Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fox Corp Class B (FOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fox Corp Class B — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Fox Corp Class B trades at $48.35 (market cap $21.80B). The key difference: Fox Corp Class B is far larger — about 4.9× ACADIA Pharmaceuticals Inc.'s market cap, and Fox Corp Class B pays a 1.14% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FOX | |
|---|---|---|
Market Cap | $4.49B | $21.80B |
Sector | Health | Media |
52-Week High | $28.06 | $67.76 |
52-Week Low | $20.06 | $44.39 |
Enterprise Value | $3.69B | $25.77B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FOX stock trades at $49.20, down 2.69% on the day, amid bearish technical signals and recent volatility following its $22 billion Roku acquisition announcement. The company shows strong fundamental performance with three consecutive quarterly earnings beats, revenue growth to $16.3 billion in 2025, and improved cash flow generation. However, technical indicators signal bearish momentum with the stock trading near support levels while analyst sentiment remains mixed with 43% buy ratings.
The outlook balances strong operational execution against acquisition integration risks. FOX's attractive valuation (P/E 13.14) and streaming expansion through Roku present growth opportunities, but high leverage and competitive pressures create near-term uncertainty. Investor focus remains on Q2 2026 earnings delivery and Roku synergy realization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
